Hims & Hers to Acquire Eucalyptus for $1.15B | Digital Health News

February 19, 2026 – U.S.-based telehealth platform Hims & Hers Health, Inc. Announced today an agreement to acquire Australian digital health company Eucalyptus in a deal valued at up to $1.15 billion. The acquisition signals a significant push by Hims & Hers to expand its personalized healthcare services into international markets, particularly in Australia, Japan, the United Kingdom, Germany, and Canada.

The deal, expected to close in the middle of calendar year 2026, will provide Hims & Hers with a direct presence in Australia and Japan, while bolstering its existing operations in Europe and Canada through established regional partnerships, according to the company’s statement. Eucalyptus operates a portfolio of consumer-focused brands, including Juniper, a weight-loss program, and Pilot, a men’s telehealth service, and has served over 775,000 customers to date.

This move comes as Hims & Hers navigates a legal challenge from Danish pharmaceutical company Novo Nordisk. The lawsuit stems from a recent U.S. Food and Drug Administration crackdown that forced Hims & Hers to discontinue its newly launched, lower-priced alternative to Novo Nordisk’s blockbuster weight-loss drug, Wegovy. The FDA’s action highlighted the regulatory complexities inherent in the rapidly evolving telehealth and direct-to-consumer pharmaceutical landscape.

Expanding Global Footprint

The acquisition of Eucalyptus represents a strategic pivot for Hims & Hers, shifting focus towards international growth. While the company has established a strong foothold in the U.S. Market, offering a range of telehealth services including hair loss treatments, skincare, and sexual health solutions, the potential for expansion abroad has become increasingly apparent. Eucalyptus’s existing infrastructure and brand recognition in key markets will accelerate this process.

Eucalyptus’s success in Australia, a market with a sophisticated healthcare system and a growing appetite for digital health solutions, is particularly attractive to Hims & Hers. Australia’s universal healthcare system, known as Medicare, provides a framework for integrating telehealth services, while its relatively small population and geographic isolation have fostered innovation in remote healthcare delivery. The acquisition will allow Hims & Hers to leverage these advantages as it seeks to replicate its success in other regions.

Navigating Regulatory Hurdles

The expansion into new international markets will not be without its challenges. Each country has its own unique regulatory framework governing telehealth and pharmaceutical sales. Hims & Hers will need to navigate these complexities carefully to ensure compliance and avoid potential legal issues. The recent dispute with Novo Nordisk serves as a cautionary tale, highlighting the importance of adhering to strict regulatory standards.

The European Union, for example, has a complex patchwork of regulations governing data privacy, medical device approvals, and cross-border healthcare services. Germany, in particular, has stringent requirements for telehealth providers, including mandatory registration and adherence to strict data security protocols. Similarly, Japan’s healthcare system is highly regulated, with a strong emphasis on quality control and patient safety.

Financial Details and Future Outlook

The deal is structured with an initial cash payment of approximately $240 million upon closing, with the remaining amount contingent on future performance milestones. Hims & Hers anticipates that the acquisition will be accretive to its earnings in the long term, driven by increased revenue and operational efficiencies. The company plans to integrate Eucalyptus’s technology platform and expertise into its existing infrastructure, creating a unified global healthcare platform.

Analysts suggest that the acquisition could position Hims & Hers as a leading player in the global digital health market. The demand for telehealth services is expected to continue to grow in the coming years, driven by factors such as an aging population, increasing healthcare costs, and the growing prevalence of chronic diseases. The company’s ability to successfully integrate Eucalyptus and navigate the regulatory landscape will be crucial to its long-term success.

The acquisition also reflects a broader trend of consolidation in the digital health industry. As the market matures, larger players are increasingly acquiring smaller, innovative companies to gain access to new technologies, expand their product offerings, and strengthen their market position. This trend is likely to continue as the industry evolves and competition intensifies.

Implications for the Australian Healthcare Landscape

The acquisition of Eucalyptus by Hims & Hers is also likely to have implications for the Australian healthcare landscape. Eucalyptus has been a key player in the growth of digital health services in Australia, offering convenient and affordable access to healthcare for a wide range of conditions. The acquisition could lead to increased investment in digital health innovation in Australia, as Hims & Hers seeks to leverage Eucalyptus’s expertise, and infrastructure.

However, some concerns have been raised about the potential impact of the acquisition on competition and consumer choice. Hims & Hers is a large, well-funded company, and its acquisition of Eucalyptus could give it a dominant position in the Australian digital health market. It remains to be seen whether this will lead to higher prices or reduced innovation.